|
2011
|
Invention
|
Tgf-beta3 mutants.
The invention provides TGF-β3s, or fragments or derivatives thereof, wherein ... |
|
2010
|
Invention
|
Inhibition of tendon adhesions. The invention provides composition having an osmolality of at lea... |
|
|
Invention
|
Improvement of tendon repair. The invention provides the use of mannose-6-phosphate (M6P) in the ... |
|
|
Invention
|
Mannose 6-phosphate for use in promoting peripheral nerve function after injury. The invention pr... |
|
|
Invention
|
Uses of mannose-6-phosphate.
There is provided the use of mannose-6-phosphate, or a salt, precur... |
|
|
Invention
|
Uses of mannose-6-phosphate. There is provided the use of mannose-6-phosphate, or a salt, precurs... |
|
2009
|
Invention
|
Non-surgical improvement of scars. The present invention provides TGF-β3 for use as a medicament ... |
|
|
Invention
|
Use of furin convertase inhibitors in the treatment of fibrosis and scarring.
The present invent... |
|
|
Invention
|
Methods and systems for determining efficacy of medicaments.
A method and apparatus for determin... |
|
|
Invention
|
Methods and systems for determining efficacy of medicaments. A method and apparatus for determini... |
|
|
Invention
|
Wound healing.
A composition for use in the treatment of wounds to inhibit scar tissue formation... |
|
|
Invention
|
Medicaments and methods for inhibition of scarring.
Provided is the use of an agonist of a GABAA... |
|
|
Invention
|
Medicaments and methods for inhibition of scarring. Provided is the use of an agonist of a GABAA ... |
|
2008
|
Invention
|
Methods for inhibition of scarring.
The invention provides new methods of treatment using TGF-β3... |
|
|
Invention
|
Methods for the inhibition of scarring.
The invention provides new methods of treatment using TG... |
|
|
Invention
|
Methods for inhibiting scarring.
The invention provides new methods of treatment using anti-scar... |
|
|
Invention
|
Methods for the inhibition of scarring. The invention provides new methods of treatment using TGF... |
|
|
Invention
|
Inhibition of scarring using tgf-beta 3. The invention provides new methods of treatment using TG... |
|
|
Invention
|
Methods for inhibiting scarring. The invention provides new methods of treatment using anti-scarr... |
|
|
Invention
|
Medicaments and methods for inhibition of non-ocular scarring.
Provided is the use of an agonist... |
|
|
Invention
|
Nr4a agonists ( 6-mercaptopurine) for inhibition of non-ocular scarring. Provided is the use of a... |
|
|
Invention
|
Secreted frizzled related protein 3 for use in the inhibition of scarring.
Provided is secreted ... |
|
|
Invention
|
Secreted frizzled related protein 3 for use in the inhibition of scarring. Provided is secreted F... |
|
|
Invention
|
Sfrp3 for use in accelerating wound healing. Provided is secreted Frizzled-Related Protein 3 (sFR... |
|
|
Invention
|
Wif-1 for accelerating wound healing. Provided is WIF-1, or a therapeutically effective fragment ... |
|
|
Invention
|
Wnt3a for inhibition of scarring.
Provided is WNT3A, or a therapeutically effective fragment or ... |
|
|
Invention
|
Use of wnt3a for acceleration of wound healing.
Provided is WNT3A, or a therapeutically effectiv... |
|
|
Invention
|
Use of wnt3a for acceleration of wound healing. Provided is WNT3A, or a therapeutically effective... |
|
|
Invention
|
Wnt3a for inhibition of scarring. Provided is WNT3A, or a therapeutically effective fragment or d... |
|
2007
|
Invention
|
Medicaments and methods for promoting wound contraction.
Provided are antagonists of FXR activit... |
|
|
Invention
|
Medicaments and methods for promoting wound contraction. Provided are antagonists of FXR activity... |
|
|
Invention
|
Lxr- antagonists for the prevention, reduction or inhibition of scarring. Provided is an antagoni... |
|
|
Invention
|
Promotion of wound contraction with a compound that promotes oestrogenic activity. The present in... |
|
|
Invention
|
Medicaments and methods comprising a compound that promotes oestrogenic activity for wound healin... |
|
|
Invention
|
Expression of tgf-beta in plastids.
Provided is a method for the expression of a TGF-β in a plan... |
|
|
Invention
|
Method of prognosis.
Provided are methods, kits and arrays for use in determining susceptibility... |
|
|
Invention
|
Method of diagnosis.
Provided are methods, kits and arrays for use in determining whether a scar... |
|
|
Invention
|
Medicaments.
There is provided the use of WNT5A, or a therapeutically effective fragment or deri... |
|
|
Invention
|
Use of antagonists of cxcl13 or cxcr5 for treating wounds of fibrotic diseases.
The invention pr... |
|
|
Invention
|
Medicaments and methods for wound healing.
The present invention relates to the manufacture of m... |
|
|
Invention
|
Promotion of wound contraction.
The present invention relates to medicaments and methods for pro... |
|
|
Invention
|
Medicaments and proteins based on tgf-β monomers for the treatment of wounds. There is provided t... |
|
|
Invention
|
Tgf-β3 mutants. The invention provides TGF-β3s, or fragments or derivatives thereof, wherein the ... |
|
|
Invention
|
Protein folding. The present invention concerns a method for folding a Transforming Growth Factor... |
|
2006
|
Invention
|
Promotion of epithelial regeneration.
The invention relates to the use of TGF-β3, or agents havi... |
|
|
Invention
|
Pharmaceutical compositions. The invention provides pharmaceutical compositions comprising TGF-β ... |
|
|
Invention
|
Data storage method.
A method for storing data in a database. The method uses configuration data... |
|
2000
|
P/S
|
Pharmaceutical and veterinary preparations; surgical and wound dressings; anti-scarring preparati... |
